Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Philadelphia-based Independence Blue Cross (IBX) will pay $22.5 million to settle DOJ allegations that it inflated diagnosis codes in Medicare Advantage to collect higher payments — a practice known as upcoding. IBX denied wrongdoing, calling it a dispute over documentation standards. The settlement is the latest in a string of MA fraud cases that have cost insurers hundreds of millions of dollars.
Philadelphia insurer agrees to $22.5M settlement over Medicare Advantage upcoding
Independence Blue Cross (IBX) has agreed to pay $22.5 million to resolve Department of Justice allegations that it knowingly submitted inflated diagnosis codes in Medicare Advantage (MA) to receive higher payments from Medicare — a practice called upcoding. The case originated from a 2020 whistleblower complaint filed by a former IBX employee.
According to the DOJ, IBX ran a retrospective chart review program from 2016 to 2020 that cherry-picked additional diagnosis codes to submit to CMS, while failing to investigate or remove inaccurate ones — as required by law. IBX denied wrongdoing, framing the settlement as a way to avoid prolonged litigation over "differing views" on documentation requirements.
By the Numbers:
Why it matters: MA upcoding fraud is a systemic and costly problem. With the U.S. spending an estimated $530 billion annually on MA, inflated diagnosis codes drain federal resources and undermine the integrity of the program — and regulators are making clear that no insurer is too big to face accountability.
